Key result
Higher baseline high-sensitivity cardiac troponin T levels correlated with a greater decline in left ventricular ejection fraction after anthracycline chemotherapy (Spearman correlation -0.54; P=0.02).
Why the study?
Do baseline levels or changes in cardiac biomarkers predict the onset of congestive heart failure or LVEF decline in cancer patients receiving anthracycline-based chemotherapy?
Population
18 consecutive patients with a pathologic diagnosis of breast cancer or non-Hodgkin lymphoma receiving…
Design
Cohort
Authors
Loading...
Baseline hscTnT may flag anthracycline patients at risk for LVEF decline; hypothesis-generating and needs prospective validation.
Observational (n=18)
Do baseline levels or changes in cardiac biomarkers predict the onset of congestive heart failure or LVEF decline in cancer patients receiving anthracycline-based chemotherapy?
Effect estimate: Spearman correlation -0.54 (95% CI -0.80 to -0.08)
p-value: p=0.02
Elevated baseline high-sensitivity cardiac troponin T levels may help identify oncology patients at high risk for developing anthracycline-induced cardiotoxicity and LVEF decline.
Blaes et al. (2015) conducted an observational in Breast cancer or non-Hodgkin lymphoma (n=18). Anthracycline chemotherapy (doxorubicin) was evaluated on Decline in left ventricular ejection fraction (LVEF) (Spearman correlation -0.54, 95% CI -0.80 to -0.08, p=0.02). Higher baseline high-sensitivity cardiac troponin T levels correlated with a greater decline in left ventricular ejection fraction after anthracycline chemotherapy (Spearman correlation -0.54; P=0.02).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: